Abstract
To the Editor. — The report1on the rapid latex agglutination test for human immunodeficiency virus (HIV) screening, using a novel recombinant envelope glycoprotein of human immunodeficiency virus, is encouraging because of its low cost, operational simplicity, and excellent sensitivity and specificity in comparison with Western blot results. Nevertheless, the encouraging findings on HIV screening among 1600 consecutive potential blood donors, tested by recently trained Zairian technicians, should not lead to universal acceptance of the latex agglutination system in the vast developing areas of Africa, Latin America, and Asia, where even the performance of otherwise efficient immunobiologicals has continued to be dismal. High ambient temperatures far exceeding 40°C, marked diurnal variation in sunlight, and humidity and drought that are a rule rather than exception in such areas have all been incriminated in the continuing failure of immunobiologicals.2Similar mishaps with otherwise promising diagnostic reagents for AIDS for such
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.